Evropska unija - slovenščina - EMA (European Medicines Agency)

laboratorios hipra s.a - živi ge-tk- virus goveje herpes z grenivom, tip 1, seva ceddel: 106,3-107,3 ​​ccid50 - imunologija - govedo - za aktivno imunizacijo goveda iz treh mesecih starosti proti goveja herpes virus tipa 1 (bohv-1) za zmanjšanje kliničnih znakov kužnih goveja rhinotracheitis (ibr) in področje virus izločanje. začetek imunosti: 21 dni po zaključku osnovnega programa cepljenja. trajanje imunitete: 6 mesecev po zaključku osnovnega programa cepljenja.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

interchemie werken de adelaar eesti as vanapere tee 14 -

Evropska unija - slovenščina - EMA (European Medicines Agency)

intervet international bv - inaktivirana celična suspenzija serotipa a, seva b3263 / 91 ornithobacterium rhinotracheale - imunologija za aves - piščanec - za pasivno imunizacijo o pitovnih piščancih, ki jih aktivno imunizacijo ženskih pitovnih rejci na zmanjšanje okužbe z ornithobacterium rhinotracheale serotip a ko je ta zastopnik sodeluje. v situacijah na terenu se pasivna imuniteta prenese v obdobju nesnosti 43 tednov po zadnjem cepljenju brejih rejcev, kar ima za posledico trajanje pasivne imunosti v pitovnih piščancih najmanj 14 dni po izvalitvi.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pharmachemie b.v. - bleomicin - prašek za raztopino za injiciranje - bleomicin 15000 i.e. / 1 viala - bleomicin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pharmachemie b.v. - bleomicin - prašek za raztopino za injiciranje - bleomicin 15000 i.e. / 1 viala - bleomicin

Evropska unija - slovenščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Evropska unija - slovenščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. nastopi imunosti so dokazali en teden po primarno cepljenje seveda za rhinotracheitis, calicivirus, chlamydophila felis in panleucopenia komponente. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Evropska unija - slovenščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Evropska unija - slovenščina - EMA (European Medicines Agency)

zoetis belgium sa  - inactivated feline rhinotracheitis virus, inactivated feline calicivirus, inactivated feline chlamydophila felis, inactivated feline leukaemia virus, inactivated feline panleukopenia virus - imunologija - mačke - za aktivno imunizacijo zdrave mačke devet tednov ali starejši proti mačji panleukopenia in mačji levkemijo virusi in proti bolezni dihal, ki jih povzročajo mačji rhinotracheitis virus, mačji calicivirus in chlamydophila felis.

Evropska unija - slovenščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.